NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Cipla gets DCGI nod to import Moderna COVID-19 vaccine
    India

    Cipla gets DCGI nod to import Moderna COVID-19 vaccine

    Cipla gets DCGI nod to import Moderna COVID-19 vaccine
    Written by Siddhant Pandey
    Jun 29, 2021, 04:12 pm 2 min read
    Cipla gets DCGI nod to import Moderna COVID-19 vaccine
    Moderna's mRNA COVID-19 vaccine will be the fourth shot to be available for use in India.

    The Drugs Controller General of India (DCGI) has reportedly allowed the pharmaceutical firm Cipla to import the COVID-19 vaccine developed by US-based biotechnology company Moderna Inc. On Monday, the company had submitted an application seeking the DCGI's approval to import the vaccine. Moderna's mRNA vaccine will be the fourth shot to be available for use in India. It is over 90% effective.

    'Permission granted for restricted use in emergency situations'

    An official source told PTI, "Drugs Controller General of India (DCGI) has granted permission to Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country as per the provisions of the New Drugs and Clinical Trial Rules, 2019 under Drugs and Cosmetics Act, 1940." "This permission is for restricted use in emergency situations in public interest," the source said.

    7 days' safety data required before roll-out: Official

    The official said, "The firm has to submit seven days safety assessment of the vaccine in first 100 beneficiaries before rolling out of the vaccine for further immunization program, according to the approval order." Cipla is seeking clarity and guidance on factors such as pricing, quantity, and indemnity clause, sources informed CNBC TV-18. Reportedly, no commercial deal has been reached yet.

    US to donate doses through COVAX: Moderna

    Additionally, the US government has notably agreed to donate some vaccine doses through the global COVAX initiative to India and has sought approval from the Central Drugs Standard Control Organisation (CDSCO), Moderna had said on Sunday. Cipla was previously close to committing over $1 billion as advance to the US firm for 50 million vaccine doses, according to PTI.

    How does Moderna's vaccine work?

    Moderna's two-dose vaccine is based on messenger RNA (mRNA) technology. The vaccine involves mRNA carrying the genetic information for SARS-CoV-2's spike protein, which it uses to invade host cells. After vaccination, this protein is translated into the viral spike protein, which triggers an immune response. The vaccine can be stored at -20°C for six months and 4°C for 30 days.

    India already using Covishield, COVAXIN, Sputnik V

    India is already using the AstraZeneca-Oxford vaccine (labeled Covishield in India), Bharat Biotech's COVAXIN, and Russia's Sputnik V in its vaccination drive, which was launched on January 16, 2021. On June 1, India had waived testing of batches at the Central Drugs Laboratory for foreign-made vaccines that have already been approved by the US FDA, the United Kingdom's MHRA, or the World Health Organization.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    Vaccine
    CIPLA
    Coronavirus
    Moderna Inc

    Latest

     ICC Women's T20 World Cup 2023: Key stats of England  ICC Women's T20 World Cup
    India vs Australia: How Virat Kohli fares against Nathan Lyon Virat Kohli
    2023 KTM 390 Adventure breaks cover: Top features explained KTM 390 Adventure
    Google Chrome to get a 'quick delete' feature on Android Google Chrome

    Vaccine

    India's 1st nasal COVID-19 vaccine by Bharat Biotech launched COVID-19
    US approves world's first vaccine for honey bees United States of America
    China slams 'distorted' Western reports on COVID-19 response, eases restrictions China
    Delhi: Government centers run out of free COVID-19 booster vaccine Delhi

    CIPLA

    Sensex closes at 57,107 points, Nifty settles at 17,007 Stock Market
    Sensex closes at 58,774 points, Nifty settles at 17,522 Ethereum
    Roche's Antibody Cocktail launched in India, priced at Rs. 59,750/dose COVID-19
    Severe side-effects after COVID-19 vaccine: What are your legal options? Oxford University

    Coronavirus

    COVID-19 outbreak has infected 80% of Chinese population China
    COVID-19: WHO urges travelers to mask up amid XBB.1.5 spread World Health Organization
    China: Hospitals cancel New Year holidays to meet patients' requirements China
    #NewsBytesExplainer: What's XBB.1.5, COVID-19 sub-variant triggering cases spike in US  COVID-19

    Moderna Inc

    Bharat Biotech completes third-phase of intranasal COVID-19 vaccine trials United Kingdom
    Moderna COVID-19 vaccine produces lasting immune response: Study Research
    Japan suspends 1.63mn Moderna vaccine doses after contamination found Japan
    No sign of Pfizer, Moderna vaccines in breast milk: Study Pfizer

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023